National Pension Service Grows Holdings in Biogen Inc. $BIIB

National Pension Service lifted its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 1.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 406,064 shares of the biotechnology company’s stock after buying an additional 4,397 shares during the quarter. National Pension Service owned approximately 0.27% of Biogen worth $87,734,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in BIIB. California State Teachers Retirement System boosted its stake in Biogen by 21,439.6% during the 2nd quarter. California State Teachers Retirement System now owns 47,535,145 shares of the biotechnology company’s stock valued at $10,270,443,000 after acquiring an additional 47,314,458 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Biogen in the 2nd quarter valued at approximately $3,453,878,000. Primecap Management Co. CA bought a new position in Biogen in the second quarter worth about $3,274,304,000. Geode Capital Management LLC boosted its holdings in shares of Biogen by 3.2% during the fourth quarter. Geode Capital Management LLC now owns 4,199,399 shares of the biotechnology company’s stock valued at $736,435,000 after acquiring an additional 130,618 shares during the period. Finally, Wellington Management Group LLP grew its position in Biogen by 5.3% in the 2nd quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company’s stock worth $673,560,000 after purchasing an additional 155,828 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Stifel Nicolaus set a $242.00 price target on Biogen in a report on Thursday. Royal Bank Of Canada increased their price objective on shares of Biogen from $240.00 to $260.00 and gave the company an “outperform” rating in a report on Tuesday, August 25th. Truist Financial upgraded shares of Biogen from a “hold” rating to a “buy” rating and raised their price objective for the company from $190.00 to $235.00 in a research note on Monday, July 13th. Guggenheim boosted their target price on Biogen from $260.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Finally, Canaccord Genuity Group upped their target price on Biogen from $245.00 to $248.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Biogen currently has a consensus rating of “Moderate Buy” and a consensus target price of $230.14.

Biogen Price Performance

Shares of NASDAQ BIIB opened at $217.15 on Friday. Biogen Inc. has a twelve month low of $135.39 and a twelve month high of $225.80. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. The firm has a 50-day moving average of $209.57 and a two-hundred day moving average of $197.36. The company has a market capitalization of $32.08 billion, a price-to-earnings ratio of 38.43, a PEG ratio of 2.38 and a beta of 0.17.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The company had revenue of $2.74 billion for the quarter, compared to analysts’ expectations of $2.46 billion. During the same quarter in the previous year, the company posted $5.47 EPS. The business’s revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, analysts expect that Biogen Inc. will post 12.39 earnings per share for the current fiscal year.

Biogen Profile

Biogen Inc is a biotechnology company focused on discovering, developing and commercializing therapies for neurological and neurodegenerative diseases. Founded in 1978, the company is headquartered in Cambridge, Massachusetts, and serves patients and healthcare providers in markets around the world.

Biogen’s portfolio includes treatments for multiple sclerosis, including Tecfidera, Vumerity, Tysabri, Avonex and Plegridy, as well as Spinraza for spinal muscular atrophy, developed in collaboration with Ionis Pharmaceuticals.